DYNDyne Therapeutics, Inc.

$20.31

$11.9752 weeks$26.80

Price

$20.31+65%1Y

1M-22%1Y+65%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value66

Quality54

Momentum47

Growth-

Strongest Value, weakest Momentum · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS. The FORCE platform utilizes an antigen-binding fragment antibody, or Fab, targeting TfR1 conjugated to a payload that we rationally design to target the genetic basis of the disease we are seeking to treat.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$3.41B

1Y Return+65%

5Y Return+23%